论文部分内容阅读
目的 总结肺类癌的临床特点、治疗方法及疗效 ,评价影响预后的因素。方法 回顾性分析 2 5例肺类癌的临床资料。其中典型类癌 (TC) 16例 ,非典型类癌 (AC) 9例。根据 1997年国际抗癌联盟分期 ,Ⅰ期 15例 (TC 14例 ,AC 1例 ) ,Ⅱ期 4例 (TC 1例 ,AC 3例 ) ,Ⅲ期 6例 (TC 1例 ,AC 5例 )。 2 5例患者均手术治疗 ,其中 18例行单纯手术治疗 ,5例行术后放射治疗 ,2例行术后化疗。结果 全组 5年和 10年生存率分别为 87%和 72 % ,单纯手术治疗患者 5年生存率为 93% ,术后辅助治疗的患者无 1例生存超过 5年。典型类癌的 5年生存率为 10 0 % ,而非典型类癌为 38%。Ⅰ期 5年生存率为 10 0 %、Ⅱ +Ⅲ期为 5 3%。单因素分析示病理类型和分期均为有显著性意义的预后因素。结论 肺类癌以手术治疗为主 ,对于Ⅲ期肺非典型类癌 ,推荐术后行辅助性化疗和 (或 )放射治疗。多数肺类癌患者可获得长期生存 ,影响预后的因素主要为病理类型和分期
Objective To summarize the clinical features, treatment methods and efficacy of pulmonary carcinoid and evaluate the factors that influence the prognosis. Methods The clinical data of 25 cases of lung carcinoid were retrospectively analyzed. Among them, 16 were typical carcinoid tumors (TC) and 9 were atypical carcinoids (AC). According to the 1997 International Anticancer Union Phase I, there were 15 cases of phase I (TC 14 cases, AC 1 case), 4 cases of phase II (TC 1 case, AC 3 cases), and 6 cases of phase III (TC 1 case, AC 5 cases) . Twenty-five patients were treated with surgery, of which 18 were treated with surgery alone, 5 were treated with postoperative radiotherapy, and 2 were treated with postoperative chemotherapy. Results The 5-year and 10-year survival rates were 87% and 72% in the whole group. The 5-year survival rate was 93% in the patients who had surgery alone. None of the postoperative adjuvant patients survived more than 5 years. The 5-year survival rate of typical carcinoids is 10%, compared with 38% of typical carcinoids. The 5-year survival rate at stage I was 10%, and the stage II+III was 5.3%. Univariate analysis showed that both histological type and stage were significant prognostic factors. Conclusion Pulmonary carcinoids are mainly surgically treated. For stage III atypical carcinoids, adjuvant chemotherapy and (or) radiation therapy are recommended. Most lung carcinoid patients can obtain long-term survival. The factors that affect prognosis are mainly pathological types and stages.